Oct 22 (Reuters) - Novavax ( NVAX ) said on Wednesday it

has signed agreements to transfer one of its U.S.-based

facilities and sell certain equipment for $60 million, without

sharing any details about the buyer.

The company said it plans to consolidate one of its

Maryland-based locations and surrounding property for cost

savings in order to focus on its research and development

efforts and partnerships.

Assignment of the lease for the facility and sale of certain

related assets are both expected to close in January of 2026 and

result in $40 million in payments to Novavax ( NVAX ).

Additionally, sale of a property adjacent to the

headquarters building is expected to result in a $20 million

payment to the company, it added.

"This planned site consolidation aligns with our commitment

to transform Novavax ( NVAX ) into a more lean and agile organization,"

CEO John Jacobs said.

The $60 million in payments is expected to result in future

cost savings of $230 million over 11 years related to both lease

expense and facility operating costs, the company said.

(Reporting by Sneha S K; Editing by Shinjini Ganguli)